IMMU Immunomedics, Inc.

5.98
+0  (3%)
Previous Close 5.80
Open 5.81
Price To book 0.00
Market Cap 634.35M
Shares 106,079,000
Volume 1,122,290
Short Ratio 6.03
Av. Daily Volume 3,878,480

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated early 2017. BLA filing due mid-2017.
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 2 update provided at ASCO June 2016. Ongoing through 2017.
SACITUZUMAB GOVITECAN
Non-small cell lung cancer (NSCLC)
Phase 2 interim data presented April 2016
Labetuzumab govitecan
Metastatic colorectal cancer (mCRC)
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus

Latest News

  1. Why Immunomedics, Inc. Got Hammered Today
  2. Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy
  3. Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan
  4. Biotech Movers: Paratek Spikes 34%
  5. Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression
  6. Battle in the Boardroom: What's Next for Immunomedics
  7. Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and Immunomedics
  8. Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017
  9. Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
  10. 3 Companies That Need to Kick Their CEO to the Curb
  11. Biotech Premarket Movers: Arena, Immunomedics, Aralez
  12. Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer
  13. Here’s What’s Moving Immunomedics, Inc. (IMMU) And Ocera Therapeutics Inc (OCRX)
  14. Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN)
  15. Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS
  16. Why Immunomedics, Inc. Jumped Higher Today
  17. Why Marathon Oil, Signet Jewelers, and Immunomedics Jumped Today
  18. Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted
  19. Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold
  20. Immunomedics Soars on Injunction Against Seattle Genetics Deal